Library / Peptides / Cognitive & Neuro / Cerebrolysin
Emerging evidence · Grade B

Cerebrolysin

Cognitive & Neuro
Evidence
Emerging
Route
Intravenous or Intramuscular injection
Frequency
Once daily for 10-20 days per cycle
Category
Cognitive & Neuro
TL;DR
Cerebrolysin is a porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids. Manufactured by EVER Neuro Pharma, it has been used clinically in over 50 countries (primarily in Europe, Asia, and Latin America) for stroke, traumatic brain injury, and dementia.
Part 01 · How it works

Mechanism.

Cerebrolysin is a porcine brain-derived peptide preparation consisting of low-molecular-weight neuropeptides and free amino acids. Manufactured by EVER Neuro Pharma, it has been used clinically in over 50 countries (primarily in Europe, Asia, and Latin America) for stroke, traumatic brain injury, and dementia. It is one of the most extensively studied neurotrophic peptide preparations.

Think of Cerebrolysin as a concentrated brain-repair smoothie containing the same growth signals your brain naturally uses to protect and rebuild neurons, delivered in a form small enough to cross into brain tissue.

Mechanism · technical
Cerebrolysin mimics the action of endogenous neurotrophic factors including BDNF, GDNF, NGF, and CNTF. Its peptide fragments activate intracellular signaling cascades involving PI3K/Akt and MAPK/ERK pathways, promoting neuronal survival, synaptic plasticity, and neurogenesis. It also reduces amyloid-beta aggregation and tau hyperphosphorylation through modulation of GSK-3beta activity.
Part 02 · Dosing & administration

How it's taken.

Values below describe how Cerebrolysin has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.

Standard dose
5-30 mL/day depending on indication
Intravenous or Intramuscular injection · Once daily for 10-20 days per cycle
Duration
10-20 day treatment courses, may repeat

Porcine brain-derived peptide preparation. Approved in many countries (not USA) for stroke and dementia. IV doses above 10 mL should be diluted and infused slowly.

Need help with reconstitution?

Use the free peptide calculator for dilution, unit conversion, and injection volume.

Open calculator
Part 03 · Safety

Side effects, rare serious events, who shouldn't.

Reported side effects
Generally well-tolerated. Reported side effects include headache, dizziness, injection site reactions, and rarely allergic reactions. Being a biological product derived from porcine brain, there are theoretical concerns about allergic responses in individuals with pork allergies. Vertigo and agitation have been reported in some trials.
Absolute · do not use
×
Epilepsy or seizure disorders (may lower seizure threshold)
×
Severe renal impairment
×
Pregnancy or breastfeeding
×
Children under 18 (unless under specialist supervision)
×
Known hypersensitivity to cerebrolysin, porcine-derived products, or any component
Interactions
Antidepressants (SSRIs, MAOIs)
Cerebrolysin has neurotrophic effects that may potentiate serotonergic or monoaminergic activity
Moderate
Anticonvulsants
May alter seizure threshold; monitor anticonvulsant levels and seizure frequency
Moderate
Lithium
Both affect neurotrophic signaling (BDNF); theoretical additive or unpredictable CNS effects
Moderate
Cholinesterase inhibitors (donepezil, rivastigmine)
Additive cholinergic effects; may increase side effects but also therapeutic benefit
Minor
Labs to monitor
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver and kidney function monitoring
CBC with Differential
Baseline and every 3 months
General safety monitoring
Urinalysis
Baseline and monthly
Monitor renal function with parenteral peptide administration
Part 04 · Research log

Every study we cite.

Each study with its published finding and a plain-language note on limitations or funding.

01
2013
0
Cerebrolysin in vascular dementia: Cochrane review
Some evidence of cognitive improvement in vascular dementia but overall evidence quality was low
Cochrane systematic review; noted high risk of bias in included trials
PMID 23543523 ↗
02
2020
0
Cerebrolysin for acute ischemic stroke
CASTA trial showed no significant improvement in primary endpoints for acute stroke
Large RCT; adequately powered
PMID 22396469 ↗
Part 05 · Cost & access

Where you can get it.

Regulatory status
Not FDA-approved in the United States. Approved and used clinically in over 50 countries including Austria, Germany, Russia, China, South Korea, and many Latin American nations. Available by prescription in those regions.
The Peptide Column takes no affiliate commission from any source.
Part 06 · Your appointment

Questions to bring.

01
What do the large clinical trials (CASTA, CARS) tell us about Cerebrolysin's efficacy for stroke?
02
Why is Cerebrolysin not FDA-approved despite decades of use in other countries?
03
What are the risks of using a porcine-derived biological product?
04
How does Cerebrolysin compare to other neuroprotective strategies for my condition?